Revenue grew 7% year-over-year to $157 million, with adjusted EBITDA margin at 48% and strong AI adoption driving both clinical and commercial momentum. Full-year guidance was raised, reflecting robust demand from pharma and hospital clients, and AI Search is expected to further boost growth in Q3.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.